Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 6/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617776 | 1.00 | DPP4 (0.45) | DPP4DPP8DPP9OPRD1OPRL1 | |
| Hydrochloric Acid SCHEMBL6165347 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1OPRL1 | |
| Hydrochloric Acid SCHEMBL6165352 | 0.98 | DPP4 (0.44) | DPP4DPP8DPP9OPRD1OPRL1 | |
| Trifluoroacetic Acid SCHEMBL2501753 | 0.91 | DPP4 (0.41) | DPP4DPP8DPP9OPRD1OPRL1 | |
| SCHEMBL5810527 | 0.83 | OPRL1 (0.41) | DPP4DPP8DPP9OPRD1OPRL1 | |
| SCHEMBL14471421 | 0.82 | DPP4 (0.48) | DPP4DPP8DPP9OPRD1OPRL1 | |
| SCHEMBL990477 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1GPR142 | |
| SCHEMBL5273058 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1GPR142 | |
| SCHEMBL990478 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1GPR142 | |
| SCHEMBL5207691 | 0.80 | DPP4 (0.49) | DPP4DPP8DPP9OPRD1GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064192-B1 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8609706-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY DISCOVERY, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8178690-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7928244-B2 | Isoxazolidine small molecules; cancer, hyperproliferation disorders; blocking antiapoptotic function | INFINITY DISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2064192-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | Infinity Discovery, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | INFINITY DISCOVERY, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213145-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | DPP4 4212/4885DPP8 3898/4885DPP9 3158/4885 |
| US-20080114167-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | DPP4 4212/4885DPP8 3898/4885DPP9 3158/4885 |
| US-20130131063-A1 | Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners | BCL2, BCL2L1, BCL2L11 | DPP4 4212/4885DPP8 3898/4885DPP9 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.